Trials / Completed
CompletedNCT02162732
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Giselle Sholler · Academic / Other
- Sex
- All
- Age
- 13 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup. This technology includes a genomic report based on DNA exomes and RNA sequencing that will be used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer in the future.
Conditions
- Neuroblastoma
- Medulloblastoma
- Glioma
- Ependymoma
- Choroid Plexus Neoplasms
- Craniopharyngioma
- Dysembryoplastic Neuroepithelial Tumor
- Meningioma
- Primitive Neuroectodermal Tumors (PNETs)
- Germ Cell Tumors
- Rhabdomyosarcoma
- Non-rhabdomyosarcoma
- Ewings Sarcoma
- Osteosarcoma
- Wilms Tumor
- Renal Cell Carcinoma
- Malignant Rhabdoid Tumor
- Clear Cell Sarcoma
- Liver Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Guided Therapy | A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles). |
Timeline
- Start date
- 2014-07-08
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
- First posted
- 2014-06-13
- Last updated
- 2025-11-03
- Results posted
- 2024-04-05
Locations
19 sites across 2 countries: United States, Lebanon
Source: ClinicalTrials.gov record NCT02162732. Inclusion in this directory is not an endorsement.